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The transforming growth factor2b (TGF2b) family of
cytokines regulates diverse cellular processes through
control of the expression of target genes. Smad proteins
are a recently identified family of signal transducers for
members of the TGF2b family. Smads act as transcrip-
tional regulators through binding to DNA and interact-
ing with a variety of transcription factors. Here, we
identified a kB site as a TGF-b-responsive region in the
3*-downstream junB promoter region. We also demon-
strate that kB sites alone are sufficient to mediate im-
mediate transcriptional activation by TGF-b. Transacti-
vation of kB sites by TGF-b requires an intact NF-kB
pathway, cooperates with known activators of this path-
way, and is mediated by Smad family members. Further-
more, we show that Smad3 interacts with p52 in vivo.
These data expand the model in which Smad proteins
undergo multiple interactions with several transcrip-
tion factors that could induce either activation or re-
pression of gene expression.
Members of the transforming growth factor-b (TGF-b)1 su-
perfamily play an essential role in the control of proliferation,
differentiation, and apoptosis and are therefore important for
the development and maintenance of most tissues. Many mem-
bers of this family have been isolated, and three major subfam-
ilies have been described as follows: TGF-bs, activins/inhibins,
and bone morphogenetic proteins (BMPs) (reviewed in Refs. 1
and 2). The effects of these cytokines are executed via ligand-
induced heteromeric complex formation of different type I and
type II serine/threonine kinase receptors. In the resulting com-
plex, the type II receptor phosphorylates the type I receptor,
which then transmits the signal into the cell (2). Smad proteins
have recently been defined as the main cytoplasmic transduc-
ing molecules in the TGF-b superfamily pathway. On the basis
of structural and functional criteria, the Smad family has been
divided into three subgroups (2–6). The receptor-regulated or
pathway-restricted Smads (R-Smads) are directly phosphoryl-
ated by type I receptors. Smad2 and Smad3 propagate TGF-b
and activin signals, whereas Smad1, Smad5, and possibly
Smad8 are specific for BMP (2–6). Receptor-activated Smads
form a hetero-oligomer with Smad4, the common mediator of
the TGF-b, activin, and BMP signaling (Co-Smad). Smad4 or
DPC4 is the only vertebrate Co-Smad identified to date (7–8).
Smad6 (9–10) and Smad7 (11–12) belong to the third class,
anti-Smads, and they antagonize signaling by R-Smads and
Co-Smads. Activation of receptor-regulated Smads disrupts the
autoinhibitory interaction between their N-terminal (MH1)
and C-terminal (MH2) domains and allows complex formation
between pathway-restricted Smads and Smad4 (2–6). These
complexes translocate into the nucleus, where they could di-
rectly bind to DNA through their MH1 domains (13–14).
A number of immediate-response genes whose promoters are
induced by TGF-b have been identified. They include plasmin-
ogen activator inhibitor-1 and fibronectin (13–15), the cyclin-
dependent inhibitors p15 and p21 (16–17), and type I and type
VII collagen (18–19). Some of them, such as plasminogen acti-
vator inhibitor-1, include Smad-binding elements, and multi-
merization of these elements confers TGF-b inducibility (13).
Oligonucleotide screening and the resolution of the crystal
structure of Smad3 MH1 domain defined the tetranucleotide
CAGA as their minimal Smad DNA-binding element (SBE)
(14–20). However, studies of promoters of Dpp-responsive
genes in Drosophila, such as vestigial and tinman, revealed
GC-rich sequences as Mad and/or Medea (Drosophila Smad
homologs) binding sequences (21). Overall, these data indicate
that Smads have relatively low DNA binding affinities and
specificity. Furthermore, growing evidence suggests that
Smads regulate transcription either by functional cooperation
with transcription factors bound to adjacent sites or through
direct association with DNA-bound transcription factors. For
example, upon ligand stimulation, the forkhead transcription
factors FAST1 and FAST2 recruit Smad 2/4 complexes to ad-
jacent sites in the Mix.2 and goosecoid promoters (22–24).
Smad3 and -4 interact with the Jun family of transcription
factors and synergistically activate AP-1 promoter sequences
(25–26). Physical interaction has also been shown between
Smads and SIP1, a member of the dEF1 family of transcrip-
tional repressors (27). A similar scenario might occur with
cooperative associations between Smad1 and Stat3 or Smad3
and vitamin D receptor. However, in these later cases, inter-
actions require the presence of coactivators such as p300/CBP
or steroid receptor coactivator-1, respectively (28–29).
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The NF-kB/rel family regulate transcription of several genes,
mainly involved in immune or inflammation responses and cell
growth control. A wide range of physiological and non-physio-
logical stimuli can activate this transcription factor (30). Five
members of the NF-kB/rel family have been identified in mam-
malian cells: p50, p52, p65/relA, relB, and c-rel. Before activa-
tion, NF-kB is in the cytoplasm of most cell types as homo- or
heterodimers. Cytoplasmic NF-kB is an inactive complex
through its association with the inhibitor proteins, IkBs
(30–31). When cells are exposed to inductors of NF-kB, IkB is
specifically phosphorylated. This phosphorylation is a signal
for ubiquitination and later degradation of IkB by the 26 S
proteasome (32). NF-kB is thus free to translocate to the nu-
cleus and activate transcription of target genes. Studies in vivo
and in vitro indicate that different NF-kB dimers have different
transcriptional activation properties. Moreover, evidence indi-
cates that interactions between NF-kB and other transcription
factors influence the ability of NF-kB to regulate gene expres-
sion in a selective manner. Consistent with this, Gerritsen et
al. (33) have found that p65 and CREB-binding protein (CBP)/
p300 interact to activate E-selectin and vascular cell adhesion
molecule 1. In addition, steroid receptor coactivator-1 interacts
with p50 subunit but not with p65 and coactivates NF-kB (34).
Several enhancer sequences have been implicated in the
transcriptional regulation of junB, a member of the AP-1 family
of transcription factors, both in the 59- and the 39-flanking
region of this intronless gene (35, 36). Recently, Jonk et al. (37)
identified two Smad-binding sequences in the mouse junB 59
promoter region that, when multimerized, mediate responsive-
ness by several members of the TGF-b superfamily. In this
report, we have investigated the transcriptional regulation of
the immediate early gene junB by TGF-b. We analyzed the
downstream region of the gene and identified an NF-kB site as
a TGF-b2 responsive region. We demonstrate that NF-kB sites
are sufficient to mediate transcriptional activation by TGF-b.
This activation requires an intact NF-kB pathway and is me-
diated by Smad family members. Finally, we show that Smad
proteins interact with NF-kB subunits. These data further
support a role for Smads as transcriptional coactivators, in
addition to their role as DNA-binding transcription factors.
MATERIALS AND METHODS
Recombinant Plasmids
Luciferase reporter plasmids pJB, pJB2028-2249 and pJB2071-2249
(36), were provided by C. Thompson. pJB2035-2072 and pJB2040-
2068CAGAmut and pJB2040-2068NF-kBmut were generated as fol-
lows: oligonucleotides 59-CTGCCCAGCAGAGTGCGCCGGGGCTTTC-
CCCGCTGAC-39 for wild type; 59-CAGTTGAGTGCGCCGGGGCTTTC-
CCCGC-39 for CAGAmut; 59-CAGCAGAGTGCGCCGATACTTTCCCC-
GC-39 for NF-kBmut, and their respective complementary counter-
parts were phosphorylated at 59 ends, annealed, and ligated with pJB,
containing the minimal junB promoter-luciferase gene construct, or
with pGL-2fos, containing the minimal c-fos promoter. pNF-kB-Luc,
which contains two NF-kB sites (59-AGGGGACTTTCCGAGAGG-39) in
front of the minimal c-fos promoter, MEKK-1DN, and IkBaDN were
kindly provided by P. Muñoz. 3TP-Lux, Smad1, Myc Smad3, and FLAG
Smad4 were provided by J. Massagué. Wild type rhoA, cdc42, and rac1
and their dominant negative and constitutively active mutants were
provided by X. R. Bustelo, whereas arf6 constructs were obtained from
J. Donaldson. Expression vectors for NF-kB subunits p50, p52, p65,
c-Rel, and RelB, were provided by J. Caamaño.
Cell Culture and Transient Transfection
Mv1Lu and COS cell lines were cultured in DMEM supplemented
with 10% fetal bovine serum. The R1B/L17 cells, provided by J. Mas-
sagué, were cultured in minimum Eagle’s medium without histidine,
supplemented with 10% fetal bovine serum, and 0.5 mM histidinol. Cells
were grown in a 10% CO2 atmosphere with 95% humidity.
Cell transfection was performed by the DEAE-dextran method as
described previously (19). When different combinations of plasmids
were used, total DNA was kept constant by the addition of empty vector.
Luciferase Assay
Mv1Lu cells were split 24 h after transient transfection, cultured in
DMEM supplemented with 0.1% fetal calf serum serum, and treated
with 200 pM human recombinant TGF-b1 (Sigma) or 1 nM BMP2
(Genetics Institute, Cambridge, MA) for 16 h. Luciferase activities were
quantified using the Luciferase Assay System (Promega). Proteasome
inhibitor, N-acetyl-Leu-Leu-norleucinal (Sigma), or brefeldin A were
added 15 min before TGF-b. Luciferase values are expressed as mean 6
S.E. of transfection experiments performed in triplicates in three to six
independent experiments.
Electrophoretic Mobility Shift Assays
Nuclear extracts were prepared from control and TGF-b- or PDB-
treated Mv1Lu as follows. Pelleted cells were resuspended in 400 ml of
ice-cold Buffer A (10 mM Hepes-KOH, pH 7.9, 10 mM KCl, 1.5 mM
MgCl2, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride,
5 mg/ml leupeptin, 5 mg/ml pepstatin, 25 mM b-glycerophosphate, 2 mM
sodium vanadate, 10 mM NaF) by flicking the tube. After a 10-min
incubation on ice, cells were vortexed for 30 s and then centrifuged. The
pellet was resuspended in 50 ml of ice-cold buffer C (20 mM Hepes-KOH,
pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM dithiothreitol, protease, and phosphatase inhibitors) and incu-
bated on ice for 20 min for high salt extraction. Cellular debris was
removed by centrifugation for 2 min, and supernatants were aliquoted
and stored at 280 °C. The protein content was determined using the
Bradford protein concentration assay (Bio-Rad) with bovine serum al-
bumin as standard. The NF-kB oligonucleotide 59-AGT TGA GGG GAC
TTT CCC AGG C-39 (Promega) was labeled with [g-32P]ATP and T4
polynucleotide kinase.
Ten micrograms of the nuclear proteins were diluted to a final vol-
ume of 20 ml in a reaction mixture containing 20 mM Tris, pH 7.9, 50 mM
NaCl, 10% glycerol, 0.1 mM dithiothreitol, 1.25 mg of poly(dI-dC). Where
indicated, unlabeled oligonucleotides or antibodies (H-119 for p50; K-27
for p52; H-286 for p65; C-19 for RelB and B-6 for c-Rel from Santa Cruz
Biotechnology) were added and the samples incubated on ice for 15 min
before adding 0.1 pmol of labeled probe (5–10 3 104 cpm). After a
20-min incubation on ice, the reaction mixture was loaded onto a 5%
polyacrylamide gel, 0.253 TBE, and 2.5% glycerol and resolved at
20 mA for 2.5 h. Gels were dried and autoradiographed.
Western Blot and Pull-down Analysis
Total Extracts—For detection of NF-kB subunits and IkBs, Mv1Lu
cells were serum-starved and treated with TGF-b for different times.
Then cells were washed twice in cold phosphate-buffered saline and
then lysed with sample buffer 13 (62.5 mM Tris, pH 6.8, 10% glycerol,
1% SDS, 100 mM dithiothreitol and 0.25 mg/ml bromphenol blue).
Pull Down—Cells were washed twice in cold phosphate-buffered
saline 48 h after transfection and lysed with 50 mM Tris, pH 7.5, 150 mM
NaCl, 0.2% Nonidet P-40, 10% glycerol, and 10 mM imidazole. Cell
debris was removed by centrifugation for 1 min. The supernatant frac-
tion was incubated with 30 ml of Ni21-NTA-agarose (Qiagen) for 1 h at
4 °C. Bound proteins were washed four times in lysis buffer, and pellet
was resuspended in sample buffer two times. Bound Smad3 was de-
tected by Western blotting using anti-Myc antibody as described above.
Western Blot—Protein extracts were resolved on 12% SDS-polyacryl-
amide gels for detection of IkBs and 10% for Smads and NF-kB sub-
units, transferred to nitrocellulose membrane, and subjected to West-
ern blot using specific monoclonal or polyclonal antibodies as follows:
FLAG-tagged Smad4, Myc-tagged Smad3, and His-tagged p52 were
detected by immunoblotting using a 1:1000 dilution of monoclonal an-
tibodies to the FLAG epitope (Sigma), the Myc epitope (9E10), and the
His epitope (Amersham Pharmacia Biotech). IkBs were detected with a
1:1000 dilution of antibodies H4 for IkBa, C-20 for IkBb, and M-364 for
IkBe (Santa Cruz Biotechnology) or the antibodies against NF-kB sub-
units described for electrophoretic mobility shift assays. Immunocom-
plexes were detected with the ECL detection system (Amersham
Pharmacia Biotech).
RESULTS
Identification of a TGFb-responsive kB Site in the junB Pro-
moter—Previously, we and others (39) have shown that junB is
an immediate early gene induced by members of the TGF-b
family. Preliminary experiments, undertaken to identify regu-
latory elements upstream of mouse junB gene, identified a
region that confers a slight response to TGF-b family members
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(Ref. 39 and data not shown), which might correspond to the
responsive enhancer described by Jonk et al. (37). We further
our study by focusing on the 39-downstream region of this
intronless gene, which has been shown to mediate induction of
its expression by serum, growth factors, phorbol esters, or
forskolin (35–36). Transfection of PJB 2028-2249-luc, which
contains these downstream response elements and the basal
junB promoter, into Mv1Lu cells elicited a small, but consist-
ent, response to TGF-b (Fig. 1B). To localize the minimal effec-
tive region, partial constructs were assayed showing that the
region from 12035 to 12072 was still fully responsive to
TGF-b, whereas the region from 12071 to 12249 did not sup-
port significant reporter induction (Fig. 1B). Sequence analysis
indicates that this responsive region contains both a single
SBE and a single kB site. To determine the specific role of
NF-kB and SBE sites in the induction of the junB expression by
TGF-b, we compared constructions containing point mutations
of the kB or SBE sites. As shown in Fig. 1C mutations of the
SBE had no effect on activation by TGF-b, whereas mutations
in the kB site completely suppressed reporter inducibility. In
addition, a reporter construct containing two consensus NF-kB-
binding sites in front of the c-fos minimal promoter conferred
stronger reporter stimulation by TGF-b (Fig. 1C). Thus, these
results seem to indicate that a kB site localized at 12054 is
sufficient for TGF-b-mediated activation of the junB gene in
both homologous and heterologous promoter contexts.
NF-kB Transcriptional Activity Is Rapidly Induced by
TGF-b—To investigate the TGF-b effect through kB sites, we
used the reporter driven by kB consensus sequences that con-
fers the strongest response. Whereas TGF-b confers 4–5-fold
induction, BMP-2 had no effect on reporter activity in Mv1Lu
cells (Fig. 2A). To assess whether induction from kB sites
required signals initiated by functional TGF-b receptors, we
used the Mv1Lu clone R1B/L17, which is unresponsive to
TGF-b due to mutations in type I receptor (38). TGF-b only
showed effects in R1B cells after reconstitution of type I recep-
tor (Fig. 2A). In addition, dose-response experiments showed
activation at TGF-b concentrations in agreement with the
affinities of TGF-b receptors (Fig. 2B).
We also performed electrophoretic mobility shift assays with
a radiolabeled NF-kB consensus oligonucleotide incubated with
nuclear extracts of cells treated with TGF-b or phorbol dibu-
tyrate (PDB), a known inductor of NF-kB activity. Fig. 2C
shows that NF-kB binding activity was increased in Mv1Lu
cells treated with both factors. However, although the PDB
effect was detected after 30 min, TGF-b effect was not detect-
able until 3 h after growth factor addition. This led us to
examine the possibility that TGF-b could induce the release of
a cytokine to the extracellular medium, which would be respon-
sible for NF-kB induction. We treated cells with TGF-b and
brefeldin A, which is a potent inhibitor of transport of newly
synthesized proteins from endoplasmic reticulum to Golgi (40).
FIG. 1. Identification of a TGFb-responsive NF-kB site. A, scheme of the junB gene with the location of the 39-downstream region (black box)
analyzed in the present report. B, analysis of TGF-b response (indicated as fold induction) of partial deletions of the 39-downstream region and the
basal reporter pJB. Mv1Lu cells were transfected with 2 mg/ml of the different constructs. One day later cells were serum-starved and treated with
TGF-b, 200 pM, for 16 h. C, wild type, mutants for the two DNA motifs (a putative SBE and a NF-kB site) found in the responsive 2035–2072 region
and a consensus NF-kB site (present in Igk or human immunodeficiency virus-long terminal repeat enhancers) were analyzed for TGF-b
responsiveness. Mutations on both sites are shown (CAGA to TTGA for CAGAmut and GGGGCTTTCC to GATACTTTCC in NF-kBmut). Data are
shown as the mean 6 S.E. of triplicates of at least five independent experiments.
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Brefeldin A, either at 1 or 5 mg/ml, had no significant effect on
reporter responses for either the kB or the Smad-responsive
construct 3TP-lux (Fig. 3A).
We then examined the time course of kB reporter induction
in further details. As shown in Fig. 3B, cells treated with
TGF-b or PDB gave the same temporal pattern of induction. A
similar pattern was also found with 3TPlux, which binds
Smads and confers immediate responses to TGF-b (13). Since
the activation profile of either NF-kB or 3TP-lux transcription
after PDB or TGF-b addition follows a very rapid pattern, these
results suggest that TGF-b induces NF-kB transcriptional ac-
tivity in an immediate manner.
A number of stimuli increase DNA binding activity through
induction of expression of specific NF-kB subunits or by control
of their translocation to the nucleus through IkBs. IkBs are
phosphorylated by a multiprotein IkB-kinase complex and then
ubiquitinated and degraded by the 26 S proteasome (32). To
test whether the TGF-b effect proceeds via an increase in
expression of NF-kB subunits, we analyzed their expression by
Western blotting. No changes were found for either p50, p52,
p65, RelB, or c-Rel up to 4 h after TGF-b addition (Fig. 3C). To
assess the role of TGF-b in IkB degradation, we also analyzed
the levels of IkB-a, -b and -e. Whereas PDB induced a signifi-
cant decrease in IkB levels, we were unable to detect significant
changes caused by TGF-b treatment (Fig. 3D). These data
suggest that TGF-b increases transactivation activity of NF-kB
through a mechanism other than the classic pathway of IkB
degradation.
TGF-b Activation Requires an Intact NF-kB Pathway—To
investigate whether NF-kB activity is required for TGF-b to
activate kB sites, we blocked this pathway at two levels. First,
we overexpressed a dominant negative mutant of IkB, which
FIG. 2. TGF-b activates NF-kB tran-
scriptional activity. R1B/L17 cells, de-
ficient in TGF-b receptor type I, and wild
type Mv1Lu cells were transfected with
the reporter vector pNF-kB-luc. 24 h
later, cells were incubated with TGF-b,
200 pM (A), or 2, 5, 20, 100, and 500 pM (B)
for 16 h, in DMEM supplemented with
0.1% fetal calf serum. Results are shown
as the mean 6 S.E. of luciferase arbitrary
units of triplicates of at least three inde-
pendent experiments. C, nuclear extracts
were obtained from Mv1Lu cells treated
with or without 100 ng/ml PDB or 1 nM
TGF-b in DMEM supplemented with
0.1% serum for different times. Extracts
(10 mg of protein) were incubated with
32P-labeled NF-kB consensus oligonucleo-
tide with or without 20-fold excess of cold
probe.
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cannot be phosphorylated and thus cannot be recognized by the
ubiquitination and degradation machinery. Overexpression of
this mutant form significantly reduced both the uninduced and
the TGF-b-induced expression of our reporter system (Fig. 4A).
In addition, we also overexpressed a dominant negative mutant
of mitogen-activated protein/extracellular signal-regulated ki-
nase kinase-1 (MEKK-1). MEKK-1 is one of the activators of
IKK (41). We found that the induction by TGF-b was also
reduced when activation of IKK by MEKK-1 was blocked.
LLnL inhibits the activity of 26 S proteasome and blocks
degradation of phosphorylated IkBs (32, Fig. 3C). Our results
showed that TGF-b did not induce activation of the reporter
when cells were treated with the proteasome inhibitor
(Fig. 4B). There were no differences between control and
treated cells when 3TPlux reporter was transfected, suggesting
that LLnL has no effect on TGF-b signaling or cell viability.
Taken together, these results indicate that TGF-b-induced
gene expression from kB binding sites requires NF-kB activity.
TGF-b Cooperates with Other Inductors of the NF-kB Path-
way—Many stimuli can activate NF-kB, such as inflammatory
cytokines, UV irradiation, phorbol esters, and other physiolog-
ical and non-physiological stimuli. To examine the potential of
TGF-b to stimulate NF-kB activity, we studied its effects in
combination with PDB. Cells were treated with a fixed dose of
PDB and, at the same time, with increasing TGF-b concentra-
tions. Combination of both stimuli had a cooperative effect on
reporter gene activity (Fig. 5A). When the same assay was
performed with a fixed dose of TGF-b and increasing concen-
trations of PDB, similar enhancement of transcription was
obtained (Fig. 5A).
During the last few years, several evidences have revealed
the implication of the Rho family of small GTPases in signal
transduction cascades that activate NF-kB through IkB degra-
dation (42). To investigate the role of these proteins in the
TGF-b effect on kB transactivation, we expressed different
members of the Rho family and their dominant negative and
constitutively active mutants. We also included the GTPase
arf6, which is involved in vesicle trafficking, as negative con-
trol. Fig. 5B shows that none of the dominant negative mutants
had any significant effect on TGF-b activation. In addition,
expression of constitutively active mutants of rac1 and cdc42
not only increased basal activation but also strongly enhanced
transcriptional induction by TGF-b.
The ability of TGF-b to cooperate with inductors of the
NF-kB pathway led us examine which NF-kB subunits were
involved in such cooperative effects. First, we preincubated
nuclear extracts of cells treated with PDB with antibodies
against NF-kB subunits and performed electrophoretic mobil-
ity shift assays with an NF-kB consensus probe. As shown in
Fig. 6A, preincubation of nuclear extracts with antibodies
against p52, p65, and RelB revealed a significantly reduced
PDB-induced band, whereas no change was obtained with an-
tibodies against p50 or c-Rel. These data suggest that TGF-b
cooperates with PDB-induced complexes containing p52, p65
and relB antigens. To assess the functional role of these sub-
units in transactivation of the NF-kB-driven reporter by
FIG. 3. Immediate effects of TGF-b do not involve IkB degradation. A, Mv1Lu cells were transfected with pNF-kB-luc or 3TPlux. The day
after transfection, cells were treated with or without 200 pM TGF-b and 5 mg/ml brefeldin A as indicated. Results are shown as the mean 6 S.E.
of triplicates of three independent experiments. B, Mv1Lu cells were transfected with the reporter vector pNF-kB-luc. 24 h later, cells were
incubated with 200 pM TGF-b for different times, and luciferase activity was assayed. Results are shown as the mean 6 S.E. of luciferase activity
relative to the induction observed at 7 h after TGF-b addition. C and D, cell extracts were obtained from Mv1Lu treated for different times with
1 nM TGF-b or 100 ng/ml PDB. Western blot analysis were performed with antibodies against NF-kB subunits (C) or IkBs (D) as described under
“Materials and Methods.”
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TGF-b, we also overexpressed all members of the NF-kB/rel
family alone and in different combinations. Expression of
NF-kB subunits had little effect on basal reporter activity
(Fig. 6B). More importantly, TGF-b was still able to induce the
NF-kB reporter system in cells with ectopically increased levels
of NF-kB subunits. In addition, some combinations even poten-
tiated TGF-b responsiveness, especially the combination of p52
and p65/RelA.
Involvement of Smads in NF-kB Transcriptional Activation
by TGF-b—Previous studies have shown that, in addition to
the regulation of NF-kB by factors which control its nuclear
translocation, the specific interaction of NF-kB with other tran-
scription factors is likely to provide an important regulatory
step that could determine selective gene activation or repres-
sion (30). The above results suggested that Smads, the main
transducing molecules of TGF-b signaling, could be involved in
such activation. To test this hypothesis, we overexpressed dif-
ferent Smads alone or in combination with NF-kB subunits and
analyzed their kB transactivation potential. Smad3, a TGF-b-
specific Smad, and Smad4 induced moderate ligand-indepen-
dent transcription and enhanced responses to TGF-b, whereas
Smad1, specific for BMPs, showed no differences compared
with control cultures (Fig. 7A). Coexpression of p52 or p65
together with Smads strongly increased the basal ligand-inde-
pendent transcription, which was further enhanced by growth
factor addition (Fig. 7A). These results seems to indicate that,
at least Smad3, Smad4, and p65, p52 might be involved in this
specific TGF-b transcriptional activation.
To further examine the involvement of these proteins, we
studied the possibility of physical interaction between the
NF-kB subunits and the Smads in vivo. After overexpression in
COS cells, copurification was performed using Ni21-NTA-aga-
rose, followed by Western blotting using anti-Myc antibody.
The weak interaction between Smad3 and p52 in the absence of
TGF2b was enhanced by cotransfection of constitutively active
type I receptor (TbR-I-TD) (Fig. 7B). However, in similar as-
says, we were unable to visualize direct interactions between
Smad4 and p52 (data not shown). These results show associa-
tion of Smad3 and p52 and indicate that nuclear translocation
of both Smad3 and p52 may be the key point in the regulation
of their transactivation potential.
DISCUSSION
Previous analysis of the 59-promoter region of the junB gene
revealed an SBE that, when multimerized in heterologous pro-
moters, mediates activation by several TGF-b family members
(37). However, in the same report, the authors were unable to
detect TGF-b inducibility by transient or stable transfection
using homologous junB promoter constructs. This fact, to-
gether with the high level of inducibility of the intact gene,
suggested that other responsive elements must be present else-
where that could mediate full responsiveness in an additive
manner. In this study, we identified an immediate-early re-
sponse element in the 39-downstream flanking region of this
intronless gene. Mutational analysis demonstrated that a sin-
gle kB site was necessary and sufficient for TGF-b responsive-
ness both in the minimal junB promoter and fused to heterol-
ogous reporters. This is consistent with previous results
showing TGF-b stimulation of the human immunodeficiency
virus 1 enhancer through kB sites or the identification of
schnurri as a TGF-b superfamily transducer in Drosophila
(43–44). schnurri is homologous to the human MBP-1/2 tran-
scription factors that bind to kB sites, where it has been sug-
gested they may act as transcriptional repressors (45).
We also demonstrated that this rapid activation required
NF-kB activity. Either blocking the activators of the pathway
or inhibition of degradation of IkB, which results in lower
nuclear translocation of NF-kB subunits, diminishes or com-
pletely blocks both basal and TGF-b-induced reporter transac-
tivation. Despite this NF-kB requirement, several lines of evi-
dence suggest that this activation differs from the classic
mechanisms. First, TGF-b-induced transcriptional activation
through kB sites does not involve immediate (up to 3 h) in-
creases in translocation of NF-kB subunits to the nucleus
(Fig. 2C) or increases in expression of NF-kB subunits
(Fig. 3C), which is consistent with previous data obtained in
HaCaT or HeLa cells (46–47). Second, classical NF-kB signal
transduction requires rapid phosphorylation (less than 10 min)
and further IkB degradation through the ubiquitin-proteasome
pathway to release active NF-kB. Addition of TGF2b does not
induce significant disappearance of IkBs or appearance of
slower migrating, phosphorylated IkBs in Mv1Lu cells treated
with proteasome inhibitors for up to 3 h. Third, although PDB
treatment, a known stimulator of IkB kinase, or expression of
activated small GTPases promotes reporter activation, TGF2b
can augment the response still further (Fig. 5). Similarly, over-
expression of NF-kB subunits, alone or in combination, also
confers synergy to the TGF-b-induced transactivation activity.
Thus, TGF-b signaling seems to converge with the NF-kB path-
way at the nuclear level. In this respect, although most of the
NF-kB activity remains sequestered by IkBs in the cytoplasm
FIG. 4. TGF-b requires an intact NF-kB pathway. A, Mv1Lu cells
were cotransfected pNF-kB-luc in combination with MEKK-1 or IkBa
dominant negative mutants or vector alone (mock). Luciferase assay
was performed 16 h after treatment with 200 pM TGF-b. Results are
expressed as mean 6 S.E. of triplicates from five independent transfec-
tions. B, Mv1Lu cells were transfected with pNF-kB-luc or 3TPlux. The
day after transfection, cells were split and treated with or without
TGF-b and 50 mM LLnL, as indicated. Results are shown as the mean 6
S.E. of triplicates of four independent experiments.
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of Mv1Lu cells, it is likely that there is a small constitutive
fraction of nuclear activity, as has been described for B cells,
corneal keratinocytes, or vascular endothelial muscle cells (30).
This small active fraction is likely to be reached by the TGF-b
signal, increasing its transactivating activity, whereas signals
that increase NF-kB translocation further cooperate in the
transcriptional response.
Although we have been unable to detect any binding to kB
sites by either bacterially or COS expressed Smad3 or -4 (data
not shown), there are still several possible mechanisms to
achieve these synergistic effects. It has been postulated that
TGF-b may signal some of its cellular responses through acti-
vation of members of the mitogen-activated protein kinase
family, such as TGF-b activated kinase-1 (TAK-1) or the c-Jun
N-terminal kinase (15, 48). These TGF-b-driven kinase path-
ways could trigger activation of nuclear NF-kB subunits
through phosphorylation. However, we did not detect activa-
tion of TAK-1 by TGF-b in vivo, and overexpression of domi-
nant negative forms of either TAK-1 or SEK-1, an upstream
activator of c-Jun N-terminal kinase, did not change reporter
inducibility (data not shown). Another possibility would be that
physical interactions between Smads and NF-kB subunits are
responsible for these cooperative effects. Here, we provide ev-
idence suggesting a role for Smads as transcriptional coactiva-
tors through physical interaction with NF-kB subunits. Over-
expression of Smad3 and Smad4 enhances transactivation of
kB sites in Mv1Lu cells. Moreover, coexpression of Smads to-
gether with NF-kB subunits, especially p52 and p65, further
increases those responses. We also demonstrate physical inter-
action of p52 and Smad3 in the absence of DNA, which is
enhanced by cotransfection of an active TGF-b receptor. These
results are consistent with data reported by Li et al. (47)
showing that chimeric Gal4-p65 constructs could support TGF-
b-dependent activation of a promoter driven by Gal4 DNA-
binding sites. Future work is necessary to discern whether
interaction upon Smad3 phosphorylation relies on unfolding
and increased nuclear localization of Smad3 or whether phos-
phorylation of C-terminal serines also increases its affinity to
bind p52.
These findings add NF-kB subunits to the list of transcrip-
FIG. 5. TGF-b cooperates with other
inductors of the NF-kB pathway. A,
Mv1Lu cells were transfected with the re-
porter pNF-kB-luc. 24 h later cells were
split and treated with PDB and/or TGF-b
as indicated for 16 h. B, Mv1Lu cells were
cotransfected with the reporter pNF-kB-
luc in combination with different mem-
bers of the family of small GTPases and
their dominant negative (DN) or constitu-
tively active (CA) forms. WT, wild type.
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tion factors that physically interact with Smads. Cooperative
physical interactions of Smads with transcription factors have
been postulated to take place through their binding to adjacent
sites on responsive promoters, as described for FAST, TFE3, or
Stat3, or through modulation of binding and/or transactivation
potential through a single enhancer site, as described for vita-
min D receptor, glucocorticoid receptor, AP-1, ATF-2, or Hoxc-8
(23–25, 28–29, 49–50). Data presented here would include
NF-kB in the latter case where, without significant changes in
NF-kB DNA binding, Smad-dependent enhancement of tran-
scriptional activity requires only kB sites. However, this does
not preclude that in the context of other promoters functional
cooperativity could rely on separate binding sites. Indeed, co-
operativity between Smads and NF-kB has been described in
the type VII collagen promoter through two separate SBE and
NF-kB enhancers (51).
Besides their interaction with transcription factors, both
Smads and NF-kB family members also associate with the
closely related transcriptional coactivators p300 and CBP.
These coactivators, in addition to their ability to modify the
chromatin structure through histone acetylation, interact with
several transcription factors through different domains and
provide them with a physical link to the basal transcriptional
machinery (5–6). The MH2 domain of Smad3 targets the C-
terminal domain of both p300 and CBP (52–54). Moreover, the
N-terminal domain of p300 and CBP binds to the activation
domain of p65 and potentiates its transactivating ability (33).
Thus, p300 and CBP could act as a linking module bringing
together both transcription factors through separate interac-
tion domains. Involvement of those coactivators is further sup-
FIG. 6. Analysis of NF-kB subunits
involved in transcriptional activa-
tion of NF-kB by TGF-b. A, nuclear ex-
tracts were obtained from Mv1Lu cells
treated with 100 ng/ml PDB in DMEM
supplemented with 0.1% serum. Were in-
dicated, extracts (10 mg of protein) were
preincubated with antibodies against
NF-kB subunits followed by incubation
with 32P-labeled NF-kB consensus probe.
B, Mv1Lu cells were cotransfected with
the reporter pNF-kB-luc in combination
with members of the NF-kB/rel family.
One day later, transfected cells were in-
cubated with TGF-b 200 pM for 16 h.
Results are shown as the mean 6 S.E.
of triplicates of five independent
experiments.
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ported by the fact that the viral protein E1A, which binds and
sequesters p300 and CBP, has also been reported to block
several gene responses to TGF2b. Among them, E1A specifi-
cally blocks the induction of junB gene expression by TGF2b
but not its induction by phorbol esters or serum (55). In addi-
tion to their interaction with transcriptional coactivators,
Smads could generate transcriptional repressor complexes by
binding to factors recruiting histone deacetylases such as TGIF
(56) or directly to DNA-binding repressors, such as SIP (27).
Thus, the relative levels of Smad coactivators and corepressors
would balance the final outcome in transcriptional activity.
Therefore, although the interaction between Smads and NF-kB
subunits may be essential for control of multiple promoters,
whether these interactions result in transcriptional activation
or repression of specific targets genes may depend on the cell
type. For example, although results presented here in epithe-
lial cells, those reported on collagen VII expression in dermal
fibroblasts (51), or in the human immunodeficiency virus-long
terminal repeats in HaCaT cells showed cooperative activation
(47), most of the effects of TGF2b and cytokines that activate
NF-kB are considered to be antagonistic in cells of hematopoi-
etic and lymphoid origin (2).
In conclusion, the present results identified an NF-kB site as
a TGF-b-responsive region in the junB promoter. We demon-
strate that NF-kB sites alone are sufficient to induce im-
mediate transcriptional activation by TGF-b. This activation
requires an intact NF-kB pathway and depends on ligand-
induced nuclear translocation of Smads where they can asso-
ciate with NF-kB subunits acting as transcriptional coactiva-
tors. These data further expand the notion that Smads undergo
FIG. 7. Involvement of Smads in
NF-kB transcriptional activation by
TGF-b. A, Mv1Lu cells were cotrans-
fected with the reporter pNF-kB-luc in
combination with Smads and members of
the NF-kB/rel family. One day later,
transfected cells were incubated with
200 pM TGF-b. Results are shown as the
mean 6 S.E. of triplicates of five inde-
pendent experiments. B, cells were trans-
fected with the indicated combinations of
Myc-Smad3, His-p52, and TbR-I(TD). Ex-
pression of proteins were determined by
direct Western blot (Wb) analysis using
epitope tags of each protein. Purification
in Ni21-NTA-agarose was performed as
described under “Materials and Methods”
followed by immunoblotting using anti-
Myc antibody.
Interaction and Functional Cooperation of NF-kB with Smads 28945
multiple interactions with different transcription factors to
induce either activation or repression of gene expression.
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